ProHance® (Gadoteridol) Injection, 279.3 mg/mL is one of the most stable macrocyclic gadolinium-based contrast agents (GBCAs), with a molecular structure that “cages” gadolinium inside.1,2 Out of 9 GBCAs in the marketplace, ProHance is the only agent approved for a cumulative dose of 0.3 mmol/kg.1
ProHance (Gadoteridol) Injection, 279.3 mg/mL provides macrocyclic GBCA stability, along with proven efficacy. The TRUTH study showed no significant difference in detection and characterization of central nervous system (CNS) lesions with ProHance® (Gadoteridol) when compared to Gadavist®. In addition, no difference was found by any reader for any of the 5 qualitative image evaluation endpoints:3
ProHance provided improved delineation and enhancement of primary and secondary neoplastic lesions of the brain and spine in children.4 In a multicenter clinical trial of 103 children, 60% of scans were enhanced, and 30-95% of scans resulted in additional diagnostic information.1
